Wells Fargo analyst David Maris says the T. Rowe Price lawsuit joins a "long list" of currently ongoing legal proceedings against Valeant Pharmaceuticals. In its most recent regulatory filing, Valeant reported more than 20 ongoing legal proceedings, Maris tells investors in a research note. "We find the growing list of investigations potentially overwhelming for any management team, let alone one that is dealing with a significant business disruption and management turnover," the analyst writes. Maris points out that Valeant CEO Joseph Papa in a recent interview disclosed that he has not set aside any funds for potential fines or litigation judgments. The analyst is currently modeling $2B for litigation expenses. Maris has an Underperform rating on Valeant with a price target range of $17-$22. The drugmaker closed yesterday down 81c to $29.19.